Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 7812 | 2.87 |
09:34 ET | 7509 | 2.87 |
09:36 ET | 919 | 2.881 |
09:38 ET | 11943 | 2.875 |
09:41 ET | 3643 | 2.9183 |
09:43 ET | 5463 | 2.91 |
09:45 ET | 200 | 2.91 |
09:48 ET | 120 | 2.905 |
09:50 ET | 1200 | 2.915 |
09:52 ET | 1084 | 2.92 |
09:54 ET | 2433 | 2.92 |
09:56 ET | 3779 | 2.92 |
09:57 ET | 6076 | 2.93 |
09:59 ET | 6488 | 2.945 |
10:01 ET | 11453 | 2.95 |
10:03 ET | 20397 | 2.965 |
10:06 ET | 12370 | 3.01 |
10:08 ET | 14576 | 3.04 |
10:10 ET | 13774 | 3.05 |
10:12 ET | 408 | 3.05 |
10:14 ET | 18454 | 3.015 |
10:15 ET | 1411 | 3.01 |
10:17 ET | 8212 | 3.04 |
10:19 ET | 600 | 3.05 |
10:21 ET | 12380 | 3.04 |
10:24 ET | 3962 | 3.0199 |
10:26 ET | 200 | 3.015 |
10:28 ET | 4057 | 3.01 |
10:30 ET | 5500 | 3 |
10:32 ET | 36277 | 3.05 |
10:33 ET | 21619 | 3.04 |
10:35 ET | 2707 | 3.03 |
10:37 ET | 868 | 3.03 |
10:39 ET | 1300 | 3.04 |
10:42 ET | 7900 | 3.035 |
10:44 ET | 31364 | 3 |
10:46 ET | 1700 | 3 |
10:48 ET | 4087 | 3.01 |
10:50 ET | 7713 | 3 |
10:51 ET | 3840 | 2.985 |
10:53 ET | 200 | 2.985 |
10:55 ET | 39488 | 2.995 |
10:57 ET | 6344 | 2.985 |
11:00 ET | 300 | 2.985 |
11:02 ET | 1541 | 2.975 |
11:04 ET | 200 | 2.975 |
11:06 ET | 200 | 2.975 |
11:08 ET | 100 | 2.97 |
11:09 ET | 4506 | 2.955 |
11:11 ET | 8662 | 2.95 |
11:13 ET | 8729 | 2.97 |
11:18 ET | 100 | 2.965 |
11:20 ET | 674 | 2.965 |
11:22 ET | 200 | 2.965 |
11:24 ET | 100 | 2.965 |
11:26 ET | 300 | 2.965 |
11:27 ET | 6786 | 2.97 |
11:29 ET | 9477 | 2.97 |
11:31 ET | 700 | 2.97 |
11:33 ET | 4019 | 2.975 |
11:36 ET | 5667 | 2.985 |
11:38 ET | 904 | 2.98 |
11:40 ET | 1373 | 2.98 |
11:42 ET | 9134 | 2.985 |
11:44 ET | 1690 | 2.985 |
11:45 ET | 6590 | 2.985 |
11:47 ET | 6888 | 2.985 |
11:49 ET | 13974 | 2.995 |
11:51 ET | 400 | 2.998 |
11:54 ET | 8625 | 2.975 |
11:56 ET | 8992 | 2.965 |
11:58 ET | 598 | 2.96 |
12:00 ET | 20852 | 2.99 |
12:02 ET | 45919 | 3.005 |
12:03 ET | 4246 | 3.015 |
12:05 ET | 5603 | 2.995 |
12:07 ET | 5723 | 2.984 |
12:09 ET | 5586 | 2.985 |
12:14 ET | 1744 | 2.985 |
12:16 ET | 598 | 2.985 |
12:18 ET | 3399 | 2.985 |
12:20 ET | 2400 | 2.98 |
12:21 ET | 8930 | 2.995 |
12:23 ET | 969 | 3 |
12:25 ET | 2100 | 2.99 |
12:27 ET | 2370 | 2.985 |
12:30 ET | 1255 | 2.98 |
12:32 ET | 3467 | 2.975 |
12:34 ET | 4515 | 2.98 |
12:36 ET | 6787 | 2.985 |
12:38 ET | 844 | 2.985 |
12:39 ET | 14621 | 2.99 |
12:41 ET | 368 | 2.995 |
12:43 ET | 8676 | 2.985 |
12:45 ET | 3948 | 2.97 |
12:48 ET | 6137 | 2.9756 |
12:50 ET | 3361 | 2.99 |
12:52 ET | 3235 | 2.989 |
12:54 ET | 109 | 2.99 |
12:56 ET | 3317 | 2.985 |
12:57 ET | 600 | 2.985 |
12:59 ET | 4000 | 2.985 |
01:01 ET | 2900 | 2.9835 |
01:03 ET | 2599 | 3 |
01:06 ET | 4360 | 3 |
01:08 ET | 1650 | 2.995 |
01:10 ET | 1100 | 2.99 |
01:12 ET | 200 | 2.99 |
01:14 ET | 8204 | 3 |
01:15 ET | 7437 | 3.015 |
01:17 ET | 3072 | 3.025 |
01:19 ET | 6959 | 3.025 |
01:21 ET | 9031 | 3.035 |
01:24 ET | 4123 | 3.035 |
01:26 ET | 485 | 3.035 |
01:28 ET | 1325 | 3.035 |
01:30 ET | 4419 | 3.045 |
01:32 ET | 558 | 3.045 |
01:33 ET | 1160 | 3.045 |
01:35 ET | 3439 | 3.045 |
01:37 ET | 1785 | 3.045 |
01:39 ET | 4958 | 3.05 |
01:42 ET | 17807 | 3.05 |
01:44 ET | 4264 | 3.05 |
01:46 ET | 1263 | 3.06 |
01:48 ET | 3043 | 3.045 |
01:50 ET | 1501 | 3.04 |
01:51 ET | 746 | 3.04 |
01:53 ET | 2155 | 3.0399 |
01:55 ET | 6773 | 3.03 |
01:57 ET | 500 | 3.035 |
02:00 ET | 2063 | 3.03 |
02:02 ET | 3453 | 3.02 |
02:04 ET | 3183 | 3.025 |
02:06 ET | 13343 | 3.025 |
02:08 ET | 15413 | 3.035 |
02:09 ET | 1772 | 3.045 |
02:11 ET | 4872 | 3.035 |
02:13 ET | 385 | 3.035 |
02:15 ET | 1248 | 3.02 |
02:18 ET | 6770 | 3.02 |
02:20 ET | 5098 | 3.035 |
02:22 ET | 1100 | 3.035 |
02:24 ET | 2656 | 3.03 |
02:26 ET | 14490 | 3.025 |
02:27 ET | 11416 | 3.025 |
02:29 ET | 6638 | 3.02 |
02:31 ET | 6784 | 3.045 |
02:33 ET | 1633 | 3.055 |
02:36 ET | 800 | 3.05 |
02:38 ET | 5651 | 3.05 |
02:40 ET | 500 | 3.055 |
02:42 ET | 4488 | 3.05 |
02:44 ET | 1600 | 3.045 |
02:45 ET | 1518 | 3.04 |
02:47 ET | 4893 | 3.055 |
02:49 ET | 300 | 3.05 |
02:51 ET | 18488 | 3.06 |
02:54 ET | 600 | 3.055 |
02:56 ET | 23461 | 3.04 |
02:58 ET | 4353 | 3.03 |
03:00 ET | 1289 | 3.02 |
03:02 ET | 9457 | 3.03 |
03:03 ET | 2200 | 3.04 |
03:05 ET | 6316 | 3.03 |
03:07 ET | 3787 | 3.0437 |
03:09 ET | 3284 | 3.03 |
03:12 ET | 3949 | 3.045 |
03:14 ET | 3618 | 3.04 |
03:16 ET | 5070 | 3.035 |
03:18 ET | 14178 | 3.035 |
03:20 ET | 1342 | 3.035 |
03:21 ET | 5279 | 3.04 |
03:23 ET | 4400 | 3.05 |
03:25 ET | 1566 | 3.04 |
03:27 ET | 2285 | 3.045 |
03:30 ET | 1720 | 3.045 |
03:32 ET | 7297 | 3.045 |
03:34 ET | 2626 | 3.045 |
03:36 ET | 33401 | 3.045 |
03:38 ET | 1795 | 3.04 |
03:39 ET | 7107 | 3.035 |
03:41 ET | 1838 | 3.035 |
03:43 ET | 14066 | 3.025 |
03:45 ET | 4089 | 3.025 |
03:48 ET | 6113 | 3.02 |
03:50 ET | 9104 | 3.03 |
03:52 ET | 21522 | 3.02 |
03:54 ET | 14252 | 3.015 |
03:56 ET | 20406 | 2.99 |
03:57 ET | 29972 | 2.98 |
03:59 ET | 202376 | 2.99 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 727.7M | -8.6x | --- |
CARGO Therapeutics Inc | 750.3M | -8.1x | --- |
Disc Medicine Inc | 698.2M | -8.0x | --- |
enGene Holdings Inc | 692.4M | -3.5x | --- |
Longboard Pharmaceuticals Inc | 764.9M | -8.9x | --- |
Hillevax Inc | 660.0M | -4.3x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $727.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 246.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.42 |
EPS | $-0.35 |
Book Value | $2.76 |
P/E Ratio | -8.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.